Drug intelligence / Profile preview

gallium Ga 68 DOTA-NeoBOMB1

Development stage: Phase 2
Lead developer: Advanced Accelerator Applications
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

Gallium Ga 68 DOTA-NeoBOMB1 is a radiopharmaceutical used as a diagnostic imaging agent in positron emission tomography (PET). It consists of the radioisotope Gallium-68 chelated to the peptide NeoBOMB1 via the DOTA chelator. NeoBOMB1 is an analog of bombesin, which targets gastrin-releasing peptide receptors (GRPRs) that are overexpressed on certain cancer cells, including prostate cancer and other solid tumors. Upon intravenous administration, this agent binds specifically to GRPRs on tumor cells, allowing for sensitive and specific PET imaging of GRPR-expressing malignancies. The primary clinical application under investigation is in detecting recurrent or metastatic prostate cancer and potentially other cancers with high GRPR expression[2][7].

Brand names: Gallium-68 NeoBGallium68 NeoBGallium 68 NeoBGallium-68 NeoBOMB1Gallium68 NeoBOMB1Gallium 68 NeoBOMB1
Other names: gallium ga 68-neob

Targets

GRPR (Gastrin-releasing peptide receptor)

Beyond the preview

Go deeper on gallium Ga 68 DOTA-NeoBOMB1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium Ga 68 DOTA-NeoBOMB1.

Explore the full profile